Single daily dose short term carbimazole therapy for hyperthyroid Graves' disease.
dc.contributor.author | MacFarlane, I A | |
dc.contributor.author | Davies, D | |
dc.contributor.author | Longson, D | |
dc.contributor.author | Shalet, Stephen M | |
dc.contributor.author | Beardwell, Colin G | |
dc.date.accessioned | 2014-12-22T15:52:55Z | |
dc.date.available | 2014-12-22T15:52:55Z | |
dc.date.issued | 1983-06 | |
dc.identifier.citation | Single daily dose short term carbimazole therapy for hyperthyroid Graves' disease. 1983, 18 (6):557-61 Clin Endocrinol | en |
dc.identifier.issn | 0300-0664 | |
dc.identifier.pmid | 6411390 | |
dc.identifier.uri | http://hdl.handle.net/10541/337552 | |
dc.description.abstract | Twenty-one patients with hyperthyroid Graves' disease were treated with carbimazole 30 mg daily, given as a single dose. Propranolol was also given for the first 3 weeks. All became clinically euthyroid with normal serum thyroxine (T4) levels, usually within 1-3 months. Patients with large goitres and raised serum alkaline phosphatase concentrations took longer to respond. In 19 patients a positive thyroid stimulating hormone (TSH) response to intravenous thyrotrophin releasing hormone (TRH) developed. Carbimazole was stopped soon after (median time of treatment 18 weeks, range 9-41 weeks) and 18 patients have been followed. Seven of these (39%) have remained in remission from hyperthyroidism for more than one year (median 77 weeks). Carbimazole 30 mg once daily is a convenient and effective treatment for hyperthyroid Graves' disease. Many patients will achieve prolonged remissions if treatment is stopped when serum T3 and T4 levels are in the low-normal range, usually 2-4 months after clinical euthyroidism has been reached. | |
dc.language.iso | en | en |
dc.rights | Archived with thanks to Clinical endocrinology | en |
dc.subject.mesh | Adult | |
dc.subject.mesh | Carbimazole | |
dc.subject.mesh | Drug Administration Schedule | |
dc.subject.mesh | Drug Therapy, Combination | |
dc.subject.mesh | Female | |
dc.subject.mesh | Graves Disease | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Male | |
dc.subject.mesh | Middle Aged | |
dc.subject.mesh | Propranolol | |
dc.subject.mesh | Thyrotropin | |
dc.subject.mesh | Thyrotropin-Releasing Hormone | |
dc.subject.mesh | Thyroxine | |
dc.subject.mesh | Triiodothyronine | |
dc.title | Single daily dose short term carbimazole therapy for hyperthyroid Graves' disease. | en |
dc.type | Article | en |
dc.contributor.department | The Christie Hospital, Manchester | en |
dc.identifier.journal | Clinical Endocrinology | en |
html.description.abstract | Twenty-one patients with hyperthyroid Graves' disease were treated with carbimazole 30 mg daily, given as a single dose. Propranolol was also given for the first 3 weeks. All became clinically euthyroid with normal serum thyroxine (T4) levels, usually within 1-3 months. Patients with large goitres and raised serum alkaline phosphatase concentrations took longer to respond. In 19 patients a positive thyroid stimulating hormone (TSH) response to intravenous thyrotrophin releasing hormone (TRH) developed. Carbimazole was stopped soon after (median time of treatment 18 weeks, range 9-41 weeks) and 18 patients have been followed. Seven of these (39%) have remained in remission from hyperthyroidism for more than one year (median 77 weeks). Carbimazole 30 mg once daily is a convenient and effective treatment for hyperthyroid Graves' disease. Many patients will achieve prolonged remissions if treatment is stopped when serum T3 and T4 levels are in the low-normal range, usually 2-4 months after clinical euthyroidism has been reached. |